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doi:10.1016/j.jtcvs.2007.11.0321076 The Journal of Thoracic and CarObjective: We sought to examine the relationship between the degree of prosthesis–
patient mismatch and long-term survival after mechanical aortic valve replacement.
Methods: Prospectively collected long-term follow-up data from 469 consecutive
patients who underwent aortic valve replacement between 1995 and 1998 were re-
viewed. The indexed effective orifice area was derived from the reference normal
values of effective orifice area divided by the patient’s body surface area. Outcome
was stratified according to the severity of prosthesis–patient mismatch: moderate mis-
match was defined as 0.65 to 0.85 cm2/m2 and severe mismatch as less than 0.65 cm2/
m2. The Cox proportional-hazards model with propensity score adjustment was used
to adjust for the observed differences in baseline characteristics between the mismatch
groups.
Results: The degree of prosthesis–patient mismatch was minimal in 57% of patients,
moderate in 39%, and severe in 4%. Predictors of clinically significant mismatch in-
cluded small aortic valve sizes (19 and 21 mm), obesity, age greater than 65 years, and
class III or IV heart failure. During a median follow-up period of approximately 7.9
years, overall survival was 77% in patients with minimal mismatch, 63% in those with
moderate mismatch, and only 47% in those with severe mismatch (P , .001). Mod-
erate or severe mismatch was a significant predictor of poorer survival (hazard ratio,
1.6; 95% confidence interval, 1.4–2.3; P , .01), even after adjustment for all signif-
icant clinical predictors (ie, propensity score; hazard ratio, 1.2; 95% confidence inter-
val, 1.0–1.5; P 5 .05).
Conclusions: In a large aortic valve surgery population, prosthesis–patient mismatch
occurred in 43% of patients, and those with significant mismatch had worse long-term
outcomes than those with minimal mismatch.
P
rosthesis–patient mismatch (PPM) occurs when a prosthetic valve implanted
during aortic valve replacement (AVR) is insufficient for a patient despite
normal prosthesis function.1 The degree of PPM is defined by the effective
orifice area (EOA) of the valve indexed to body surface area (BSA). Hemodynamic
compromise occurs when indexed EOA is less than 75% of native EOA, leading to
high postoperative transvalvular gradients and reduced regression of left ventricular
hypertrophy.2 Significant mismatch has been reported in up to 60% of patients under-
going mechanical AVR.
However, the effect of PPM on survival remains controversial, possibly because
the methods used to measure native EOA vary among studies. In some studies
PPM has been shown to be an independent predictor of short-term survival in patients
who have undergone AVR.3 Limited data suggest that the persistence of high gradi-
ents and limited regression might be an obstacle to improvement and might adversely
affect both long-term survival and functional quality of life.2,4 We sought to determine
whether PPM is associated with significantly reduced long-term survival in patients
undergoing AVR.diovascular Surgery c May 2008
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AVR 5 aortic valve replacement
BSA 5 body surface area
CI 5 confidence interval
EOA 5 effective orifice area
HR 5 hazard ratio
PPM 5 prosthesis–patient mismatch
OR 5 odds ratio
Materials and Methods
Clinical, operative, and outcome data were prospectively
collected from the Texas Heart Institute Research Database
(THIRDBase), a comprehensive, longitudinal clinical registry of
outcomes for more than 150,000 patients treated for cardiovascular
disease at the Texas Heart Institute at St Luke’s Episcopal Hospital.
THIRDBase includes a wide range of data on all patients admitted to
our institution with a diagnosis of cardiovascular disease. Written in-
formed consent was obtained at hospital admission from all regis-
tered patients, and the study was approved by the institutional
review board for the Texas Heart Institute at St Luke’s Episcopal
Hospital.
We examined records of 492 adult patients ($18 years old) who
underwent mechanical AVR for aortic stenosis at the Texas Heart
Institute from January 1, 1993, through December 31, 1998, and
agreed to participate in a telephone survey. In addition, non-Texas
residents were excluded from the present study to obtain accurate
long-term survival information from the state database. The decision
to perform AVR was made by the treating physicians in conjunction
with their patients. We excluded patients who had native or pros-
thetic endocarditis (defined as blood culture–positive or systemic
sepsis with the clinical syndrome of infective endocarditis,
culture-positive valvular vegetations, or diagnosed or suspected
endocarditis that required antibiotic treatment; n 5 21) or concom-
itant procedures other than coronary artery bypass grafting (n5 2).
The remaining 469 patients were included in the present study.
Patient histories were obtained by means of interview at hospital
or clinic presentation and were entered prospectively into the data-
base. Hypertension was defined as either blood pressure greater than
130/90 mm Hg or the combination of a history of hypertension and
current use of antihypertensive medications. Diabetes mellitus was
defined as a fasting blood sugar level of greater than 125 mg/dL
or the use of antidiabetic agents. Renal insufficiency was defined
as a serum creatinine level of 2 mg/dL or greater. Obesity was de-
fined as a body mass index of 30 or greater. Coronary artery disease
was defined either as significant stenosis (.50%) in the left main ar-
tery or in all 3 major epicardial vessels. Peripheral vascular disease,
cerebrovascular disease, and chronic lung disease were determined
from each patient’s medical history before the admission date. Pre-
vious myocardial infarction was deemed to be present if the patient
had a history of myocardial infarction, coronary intervention, or cor-
onary artery bypass surgery for myocardial infarction or if there
were significant Q waves on the patient’s surface electrocardiogram.
Patient size was represented by BSA, which was calculated from
height and weight. The indexed EOA was derived from the reference
normal values of EOA divided by the patient’s BSA. The reference
values for EOA were based on previously published data.3 TheThe Journal of Thoraindexed EOAs for St Jude hemodynamic plus valves were obtained
through direct communication with the manufacturer, and these num-
bers were found to be in concordance with previously published
data.5,6 Outcome was stratified according to the severity of PPM: min-
imal mismatch was defined as an indexed EOA of greater than 0.85 cm2/
m2, moderate mismatch as an indexed EOA of 0.65 to 0.85 cm2/m2, and
severe mismatch as an indexed EOA of less than 0.65 cm2/m2.
The study end point was all-cause mortality. Survivorship was
determined from the Texas State Department of Vital Statistics
database, hospital records, and telephone follow-up. The Depart-
ment of Vital Statistics keeps records of all births and deaths that
have occurred in Texas from 1903 to the present. Consequently,
follow-up information was available for all of the patients enrolled
in the present study.
Most patient characteristics and event rates were recorded as
binary categorical variables (ie, present or not present) and reported
as percentages. The Pearson c2 test was used to analyze discrete
variables, and the Student t test was used to analyze continuous vari-
ables. Logistic regression models using a forward stepwise variable
selection process were developed to determine which clinical and
angiographic variables were associated with PPM.
Cumulative survival was estimated with the Kaplan–Meier
method and compared between groups by using a log-rank test.
Cox proportional-hazards regression models were developed to
determine whether severe PPM was associated with survival after
adjustment for potential confounders. The assumption of linearity
was evaluated for the continuous measures by using restricted cubic
spines. Adjusted analyses were performed for the study cohort over-
all and stratified by age and sex. Further analysis was conducted to
control for selection bias related to PPM. Unconditional logistic
regression was used to estimate a propensity score for each patient.
This score was then incorporated into a proportional-hazards model
as a continuous variable with all predictor variables significant at
a 2-tailed nominal P value of less than .20 in the univariate analysis.
Hazard ratios (HRs) and corresponding 95% confidence intervals
(CIs) were computed with associated P values. All analyses were
performed with SAS 6.09 software (SAS Institute, Cary, NC) for
the VAX/VMS operating system.
Results
The median follow-up period was approximately 7.9 years
(interquartile range, 5.0–10.0 years) for the 469 patients
included in the study. Overall, 31.8% of the cases were con-
comitantly performed with coronary artery bypass grafting.
During this era, St Jude standard valves (St. Jude Medical,
St Paul, Minn) were the preferred valve and accounted for
90.2% of our implantations (Table 1). Nineteen- and 21-
mm valves were placed in 27.5% of patients. The degree of
PPM was minimal in 57%, moderate in 39%, and severe in
only 4% of patients. Seventy-five percent of severe mismatch
cases occurred after implantation of smaller (ie, 19 and 21
mm) mechanical aortic valves. This severe mismatch
occurred in 11% of all patients who received 19- or 21-mm
mechanical valves.
We examined the patients’ baseline demographics, both as
a whole and according to the degree of PPM (Table 2).
Patient variables more commonly associated with greatercic and Cardiovascular Surgery c Volume 135, Number 5 1077
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Size (mm)
19 (n 5 16) 21 (n 5 113) 23 (n 5 126) 25 (n 5 111) 27 (n 5 90) 29 (n 5 13) Total (n 5 469)
Type
Carbomedics 2 (0.4%) 6 (1.3%) 8 (1.7%) 5 (1.1%) 2 (0.4%) 0 (0%) 23 (4.9%)
St Jude HP 4 (0.9%) 19 (4.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 23 (4.9%)
St Jude STD 10 (2.1%) 88 (18.8%) 118 (25.2%) 88 (22.6%) 13 (18.8%) 88 (2.8%) 423 (90.2%)
HP, Hemodynamics plus; STD, Standard.degrees of mismatch included hypertension, increasing age,
and higher BSA. Female sex was associated with more severe
mismatch; however, this association is probably substantially
confounded by the smaller prosthetic valve sizes often used
in the female patients. No significant differences were found
in other domains at baseline. Predictors of moderate or severe
mismatch included small aortic valve sizes (19 and 21 mm),
with an odds ratio (OR) of 8.3 (95% CI, 5.1–13.6; P, .01);
obesity, with an OR of 3.4 (95% CI, 1.9–6.1; P , .01); and
age greater than 65 years, with an OR of 1.9 (95% CI, 1.2–
3.0; P , .01).
Overall survival was 90% at 1 year, 79% at 5 years, and
64% at 12 years. Twelve-year survival was 77% in patients1078 The Journal of Thoracic and Cardiovascular Surgery c Mawith minimal mismatch, 63% in those with moderate
mismatch, and only 47% in those with severe mismatch
(Figure 1). Patients with moderate or severe mismatch had
significantly poorer survival than patients with minimal
mismatch (P 5 .0076).
In a univariate model moderate or severe mismatch was
strong and significantly associated with long-term mortality
(HR, 1.6; 95% CI, 1.4–1.8; P, .001) and remained an inde-
pendent predictor after adjustment for patient age and sex
(HR, 1.4; 95% CI, 1.2–1.6; P5 .04). In a propensity-adjusted
model there was a borderline statistically significant relation-
ship between moderate or severe mismatch and increased
mortality (HR, 1.2; 95% CI, 1.0–1.5; P 5 .05; Table 3).TABLE 2. Demographics of patients and their prostheses according to degree of prosthesis–patient mismatch
Degree of PPM
All patients (n 5 469) Minimal (n 5 267) Moderate (n 5 183) Severe (n 5 19) P value
Preoperative characteristics
Age (y) 56.1 6 11.5 53.6 6 12.5 59.5 6 8.9 59.1 6 9.3 ,.001
Female sex (%) 33.3 26.9 40.9 47.3 .001
Ejection fraction (%) 49.2 6 13.5 48.8 6 14.2 49.6 6 12.3 50.2 6 14.1 .84
Body surface area (m2) 2.0 6 0.2 1.9 6 0.2 2.0 6 0.2 2.1 6 0.2 .006
Preoperative comorbidities
Hypertension (%) 47.3 42.6 54.6 57.9 .005
Insulin-dependent diabetes (%) 5.1 4.5 6.0 5.2 .53
Dyslipidemia (%) 23.8 19.6 28.9 31.6 .021
Smoking (%) 44.3 44.5 44.2 42.1 .86
Left main or 3-vessel disease (%) 20.6 20.4 21.9 10.5 .77
Unstable angina (%) 18.1 16.4 20.2 21.1 .30
Myocardial infarction (%) 2.4 3.0 1.6 0.0 .24
NYHA heart failure class III or IV (%) 85.1 81.2 90.1 89.5 .008
LVEF #35% (%) 18.7 21.2 15.8 13.3 .38
Cerebrovascular accident (%) 6.4 5.6 7.7 5.3 .54
Chronic renal failure (%) 6.6 4.1 10.4 5.3 .038
Chronic lung disease (%) 26.1 23.9 28.4 31.6 .23
Obesity (%) 14.9 8.6 21.9 36.8 ,.001
Operative characteristics
Urgent surgical intervention (%) 7.5 6.7 7.7 15.8 .013
Concomitant CABG (%) 31.8 29.6 35.5 26.3 .40
Clamp time (min) 51.2 6 25.3 48.0 6 21.5 55.1 6 26.5 59.4 6 50.8 .006
Small valve size: 19–21 mm (%) 27.5 10.5 47.5 73.7 ,.001
PPM, Prosthesis-patient mismatch; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; CABG, coronary artery bypass grafting.
*Minimal mismatch, Indexed effective orifice area greater than 0.85 cm2/m2; moderate mismatch, indexed effective orifice area of 0.65 to 0.85 cm2/m2; severe
mismatch, indexed effective orifice area of less than 0.65 cm2/m2).y 2008
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icant predictor of long-term mortality in univariate analysis
(HR, 0.3; 95% CI, 0.2–0.5; P , .01) but not in multivariate
analysis (HR, 0.9; 95% CI, 0.6–1.3; P 5 .54). Because the
relationship between the indexed EOA and the risk of mortal-
ity was not linear, we also performed a logarithmic transfor-
mation of the indexed EOA and found a similar trend.
Discussion
Valve size in relation to BSA has been proposed as a predictor
of survival after valve operations. In this study of 469 patients
Figure 1. Long-term survival after aortic valve replacement by
degree of prosthesis-patient mismatch (PPM). Minimal PPM, In-
dexed effective orifice area of greater than 0.85 cm2/m2 effective
orifice area; moderate PPM, indexed effective orifice area of
0.65 to 0.85 cm2/m2; severe PPM, indexed effective orifice area
of less than 0.65 cm2/m2.
TABLE 3. Risk-adjusted association of clinical and
operative demographics with long-term mortality
Variable Hazard ratio 95% CI P value
Univariate model
Moderate or severe mismatch* 1.6 1.4–2.3 ,.01
Age- and sex-adjusted model
Moderate or severe mismatch* 1.4 1.2–1.6 .04
Propensity-adjusted model
Moderate or severe mismatch* 1.2 1.0–1.5 .05
LVEF #35% 1.3 1.1–1.7 .01
Urgent surgical intervention 2.1 1.5–2.3 ,.01
Age .65 y 1.9 1.5–2.3 ,.01
Chronic renal failure 1.4 1.1–1.8 ,.01
Cerebrovascular accident 1.6 1.2–2.2 ,.01
Left main or 3-vessel disease 1.3 1.1–1.6 .01
Diabetes 1.6 1.3–2.0 ,.01
Smoking 1.2 1.0–1.5 .01
CI, Confidence interval; LVEF, left ventricular ejection fraction. *Indexed
effective orifice area of 0.85 cm2/m2 or less.The Journal of Thorawith a median follow-up of 7.9 years, moderate or severe
PPM (indexed EOA , 0.85) was associated with an in-
creased risk of mortality in univariate analysis and with pro-
pensity score adjustment in multivariate analysis. The
strengths of our study include a diverse patient population
and long follow-up. Also, we included patients with several
types of valve prostheses, and our population was represen-
tative of that seen in general clinical practice.
Previous short- and intermediate-term survival analyses
have not consistently identified PPM as an independent
predictor of adverse outcomes.7,8 It is therefore agreed that
severe PPM increases early mortality, whereas its effect on
late results is less clear. Clinically, severe PPM appears to
be associated with a higher incidence of late symptoms of
heart failure and less regression of left ventricular hyper-
trophy, as determined by means of echocardiographic
analysis.9-11 Recently, an analysis from the Mayo Clinic
identified severe PPM as an independent predictor of long-
term mortality in patients with small aortic valve prosthe-
ses.12 However, it is important to note that only patients
with small valves (19 and 21 mm) were included in that
study. Current mechanical valves provide low systolic gradi-
ents and acceptable orifice areas in patients with a small aortic
root, but these devices necessitate anticoagulation, thus
incurring a risk of hemorrhagic complication in older pa-
tients.13 The study also excluded all short-term deaths, which
might have biased the results because short-term mortality is
higher in patients with moderate or severe PPM. It is impor-
tant to note that in our study patients undergoing aortic root
enlargement concomitant with AVR were not excluded. In
fact, throughout our study period, an attempt was made to up-
size the aortic root to accommodate larger valve sizes. As
a consequence, severe PPM was found in only 4% of patients.
Age greater than 65 years was an independent risk factor
for long-term mortality in our patients. Because the popula-
tion is aging, the incidence of degenerative aortic valve dis-
ease continues to grow, and the potential adverse effect of
PPM on long-term survival in the elderly population is of in-
creasing concern. Some studies have suggested that the effect
of PPM is more important in younger patients14 and that
elderly patients simply might not live long enough to mani-
fest a survival decrement from significant PPM.15 However,
we found no interaction between age and PPM. Instead, PPM
predicted long-term mortality regardless of patient age.
Prosthesis size in our population was defined by the
in vivo functional dimensions of the prosthesis and not by
geometric dimensions. Geometric dimensions are usually
obtained from the valve size reported on the label by the man-
ufacturer, but this number variably refers to the diameter of
the external sewing ring and to the diameter of the internal
orifice. Pibarot and Dumesnil2 have suggested that rather
than using geometric prosthesis dimensions, projected
EOA, which is computed from in vivo EOA, should be
used because it is a more physiologic measure.cic and Cardiovascular Surgery c Volume 135, Number 5 1079
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to-severe PPM and long-term survival was only modestly
significant after adjustment for age and sex (P 5 .05) and
after stepwise modeling with propensity scoring (P 5 .04).
One possible explanation for this finding is that our study
only included 469 patients, which might not have been
enough to adequately examine 20 variables. Thus our results
might underestimate the true independent association
between substantial PPM and long-term outcomes. It is quite
possible that if we had more patients, the association between
moderate-to-severe PPM and long-term survival would
become more significant.
Our study has other limitations. First, this was not a ran-
domized trial; therefore surgical procedures were performed
at the discretion of the individual surgeon, and patient
characteristics in the 3 mismatch groups were intrinsically dif-
ferent. Propensity score adjustment was used to reduce
treatment selection bias, allowing for a fairer comparison.
Yet without treatment randomization, the possibility that
there were unmeasured confounding variables cannot be ex-
cluded. The small number of patients in the severe mismatch
group also limits our ability to draw firm conclusions about
such patients or other types of patients with smaller valves.
Second, more than 90% of the valves used in our cohort
were older St Jude Medical models, and the newer prostheses
have better hemodynamic performance and are associated
with a lower prevalence and severity of PPM, which might
translate into better outcomes. Thus our results might not
be generalizable to patients with newer prosthetic valves.
Third, although they have been validated multiple times in the
past,2,16 most of our ‘‘reference values’’ for aortic valve prosthe-
sis EOA were derived from the results of a single study and were
therefore crucially dependent on the methods used in that study.
Finally, our models do not include the cause of death, and
thus our models might be based on mortality unrelated to
aortic valve disease. However, all-cause mortality is an
appropriate end point to follow because it accounts for both
cardiac and systemic disease and is unaffected by the report-
ing and misclassification bias potentially introduced by a
physician’s filing of a death report.17
In conclusion, in a large aortic valve surgery population,
substantial PPM occurred in 43% of patients. Moderate or
severe mismatch was most likely to occur in patients with
larger BSA, older age, and smaller prosthesis size. The pa-
tients with substantial mismatch had significantly worse
long-term outcome than the patients with minimal mismatch.
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